Skip to Content

'
Gabriel Lopez-Berestein, M.D.

Present Title & Affiliation

Primary Appointment

Professor of Medicine, Cancer Biology, and Experimental Therapeutics, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor of Biomedical Sciences, Department of Integrative Biology & Pharmacology, The University of Texas Health Science Center at Houston, Houston, TX
Professor of Pharmacology, Department of Pharmacology, The University of Texas Medical School at Houston, Houston, TX
Adjunct Professor, Department of Bioengineering, Rice University, Houston, TX
Professor of NanoMedicine and Biomedical Engineering, UTHealth, Houston, TX
Adjunct Professor of Surgery, University of Puerto Rico School of Medicine, San Juan, PR

Education & Training

Degree-Granting Education

1976 Universidad de Navarra, Pamplona, Spain, MD, Immunology
1970 Universidad de Puerto Rico, Rio Piedras, PR, BS, Pre Med

Experience/Service

Academic Appointments

Faculty, University of Texas Graduate School of Biomedical Sciences, Houston, TX, 2004-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Hussein YR, Sood AK, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z, Roh J, Han HD, Lopez-Berestein G, Ali-Fehmi R. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol 43(10):1638-44, 10/2012. e-Pub 3/19/2012. PMID: 22436627.
2. Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33(10):1843-53, 10/2012. e-Pub 5/10/2012. PMID: 22581827.
3. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupaimoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366(7):610-8, 2/16/2012. PMCID: PMC3296780.
4. Li L, Cao XH, Chen SR, Han HD, Lopez-Berestein G, Sood AK, Pan HL. Upregulation of Cavß3 subunit in primary sensory neurons increases voltage-gated Ca2+ channel activity and nociceptive input in neuropathic pain. J Biol Chem 287(8):6002-13, 2/2012. e-Pub 12/2011. PMCID: PMC3285367.
5. Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LM. Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine Tumors. Gastroenterology 141(5), 11/2011. PMCID: PMC3202668.
6. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death. J Natl Cancer Inst 103(21):1596-612, 11/2011. PMCID: PMC3206039.
7. Khakoo AY, Liu PP, Force T, Lopez-Berestein G, Jones LW, Schneider J, Hill J. Cardiotoxicity due to Cancer Therapy. Tex Heart Inst J 38(3):253-256, 2011. PMCID: PMC3113124.
8. Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One 6(3):e17918, 2011. e-Pub 3/21/2011. PMCID: PMC3061867.
9. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 6(7):e21121, 2011. PMCID: PMC3130734.
10. Samuel S, Gaur P, Fan F, Xia L, Gray MJ, Dallas NA, Bose D, Rodriguez-Aguayo C, Lopez-Berestein G, Plowman G, Bagri A, Sood AK, Ellis LM. Neuropilin-2 Mediated ß-Catenin Signaling and Survival in Human Gastro-Intestinal Cancer Cell Lines. PLoS One 6(10):e23208, 2011. e-Pub 10/2011. PMCID: PMC3197582.

Grant & Contract Support

Title: Clinical Translation of Therapeutic siRNA in Solid Malignancies
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator
Principal Investigator: Coleman
Duration: 12/1/2011 - 11/30/2014
 
Title: Nanotechnology Platforms for Targeting Pathological Vasculature for Therapy and Imaging
Funding Source: Alliance for NanoHealth
Role: Principal Investigator
Duration: 4/15/2011 - 4/14/2013
 
Title: Texas- Center of Cancer Nanotechnology Excellence
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2010 - 7/31/2015
 
Title: New Reagents for Synthesis of High Potency siRNA
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2010 - 8/31/2013
 
Title: University of Texas M. D. Anderson SPORE in Melanoma - Project 4: Targeting Angiogenesis Utilizing siRNA Nanoliposomes as a New Modality for Treatment of Melanoma (Co-PI Wen Jen Hwu, Bar-Eli, Lopez-Berestein)
Funding Source: NIH/NCI
Role: Co-Leader
Principal Investigator: Elizabeth Grimm
Duration: 6/1/2009 - 5/31/2014
 
Title: Highly specific targeting of the TMPRSS2/ERG fusion gene in prostate cancer using liposomal nanotechnology.
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Co-Investigator
Principal Investigator: Bulent Ozpolat
Duration: 5/15/2009 - 5/14/2013
 
Title: UPRCCC/MDACC Partnership for Excellence in Cancer Research
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/29/2008 - 8/31/2013

Last updated: 3/8/2013